Glucotrack, Inc. · NASDAQ:GCTK
Glucotrack — Investor Presentation (January 2024)
24 slides from Glucotrack's investor presentation, January 2024
Slide 1: Corporate Summary
Corporate Summary NASDAQ: GCTK January 2024
Slide 2: Important Disclaimers
Important Disclaimers This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this presentation that are not statements of historical fact may be deemed to be forward-looking statements. Without limitin
Slide 3: Introduction
Introduction Glucotrack is a US-based NASDAQ-listed medical device company focused on the design, development and commercialization of novel technologies for use by people with diabetes. 3
Slide 4: Company History
Company History 2001 Company founded as Integrity Applications, Inc. 2010 Company goes public on the OTC Markets under symbol IGAP 2013 Obtained CE Mark for non-invasive glucose monitoring technology 2018 Limited commercial release of non-invasive glucose monitoring product 2021 NASDAQ Listing; Comp
Slide 5: Mission
Mission Our mission is to become a leader in diabetes management by bringing to market innovative, novel, and cost-effective technologies that address multiple verticals within the diabetes market. 5
Slide 6: Diabetes at a Glance – Globally
Diabetes at a Glance – Globally Geography 2021 2045 Increase GLOBAL 537 M 783 M 46 % North American & Caribbean 51 M 63 M 24 % South & Central America 32 M 49 M 50 % Europe 61 M 69 M 13 % Middle East & North Africa 73 M 136 M 87 % Africa 24 M 55 M 134 % Southeast Asia 90 M 152 M 68 % Western Pacific
Slide 7: Diabetes at a Glance - Costs
Diabetes at a Glance - Costs Diabetes-related increase in global health expenditure has grown from $232B (2007) to $966B (2021), estimated to reach $1.03T (2030) 1 Complications from diabetes2 • Cardiovascular disease • Nerve damage (neuropathy) • Kidney damage (nephropathy) • Eye damage (retinopath
Slide 8: Diabetes at a Glance – US Morbidity / Mortality
Diabetes at a Glance – US Morbidity / Mortality LEADING CAUSES OF DEATH 800,000 700,000 600,000 500,000 400,000 300,000 200,000 100,000 0 BLINDNESS: Diabetes is the leading cause of new cases of blindness among adults aged 18–64 years. 90% of blindness caused by diabetes is preventable. HEART DISEAS
Slide 9: US Diabetes Market Overview
US Diabetes Market Overview Type 1 Diabetes Type 2 Diabetes Prediabetes Gestational (1.9M people) (34M people) (98M people) (2-10% of pregnancies) Body produced insulin is Body produced insulin is Body no longer able to produce Body produced insulin is insufficient, but not severe What insufficient
Slide 10: Commercially-Available Glucose Monitoring Options
Commercially-Available Glucose Monitoring Options Blood Glucose Monitors (BGM’s) Continuous Glucose Monitors (CGM’s) Spot/Point-in-Time – measures glucose Method level at a single point in time Continuous – measures glucose every few minutes for duration of sensor life Company Dozens of manufacturer
Slide 11: Current CGM Annual Costs
Current CGM Annual Costs CGM - Annual Cost (Cash Price) Product Sensor Cost Monthly Cost Annual Cost $8,000 $7,000 Abbott $ 71.001 $ 142.00 $ 1,917.00* FreeStyle Libre 3 $6,000 Senseonics $5,000 $ 2,100.002 $ 350.00 $ 4,200.00** Eversense E3® $4,000 Dexcom $ 125.671 $ 377.00 $ 4,649.67*** G7 $3,000
Slide 12: CGM Market Current Size & Growth
CGM Market Current Size & Growth • Global 2Q23 CGM revenue was $2.4 Billion, with strong growth rates. 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 • Growth seemingly reflects market expansion to include a broader Revenue Growth 18% 16% 12% 11% 16% 19% range of people with diabetes, due to Medicare’s expanded CGM
Slide 13: CGM Market Penetration Challenges
CGM Market Penetration Challenges Despite CGM maturity, US Type 1 diabetes market is only 55% penetrated1 Wearability of sensor and accuracy are major barriers2,3 • Hassle of wearing all the time Abbott Dexcom • Do not like device on body FreeStyle Libre 3 G7 • Do not want people to see • Too much e
Slide 14: CGM Users' Challenges
CGM Users’ Challenges Signal loss, inaccurate readings, and sensors not lasting their full life are challenges that over one-third of current CGM users surveyed have faced Frequent signal loss 41% Inaccurate glucose readings 37% Doesn't last full sensor life 34% Alarms too much 33% Sensor falls off
Slide 15: Continuous Blood Glucose Monitoring (CBGM)
Continuous Blood Glucose Monitoring (CBGM) • Founded on best-in-class glucose monitoring and cardiac monitoring technology • Differentiated glucose monitoring technology • CBGM aims to combine the best of BGM & CGM • Measures blood glucose vs interstitial tissue • 100% implantable (all components un
Slide 16: Strong Positive Reaction to Concept
Strong Positive Reaction to Concept Over 50% of respondents (N=757) are interested in the implantable CBGM concept. Current CGM users had the highest interest and likelihood to acquire, followed by CGM ex-users. Would love not having Most Appealing Aspects Sounds like the best something attached to
Slide 17: Market Opportunity for Implantable CGM
Market Opportunity for Implantable CGM • Implantable CGM market traditionally US CGM Market Opportunity defined as Total US Diabetes Market 38M • T1D • T2D on intensive insulin therapy # T1D 1.8M1 # T2D Insulin Intensive Therapy (4+ injections/day) 2.4M1 • Implantable CGM market now includes new pat
Slide 18: Meaningful Value Proposition for Patients, Providers, Payors
Meaningful Value Proposition for Patients, Providers, Payors Glucotrack CGM is an intravascular implantable continuous blood glucose monitoring system with unmatched longevity and discretion in a set and forget model that has the potential to significantly increase compliance and patient satisfactio
Slide 19: Development & Commercialization Timeline
Development & Commercialization Timeline 2024 2025 2026 2027 2028 Preclinical Animal Studies Clinical Studies (First in Human & Pivotal) Product Development, Validation, and Manufacturing Regulatory Submissions & Approval Commercialization 19
Slide 20: Management
Management Paul has many years developing innovative diabetes management technologies, including as VP of R&D at MetaCure, a Paul V. Goode, PhD neurostimulator device for Type 2 diabetes; Director of Engineering and Algorithm Development at DexCom, a global continuous glucose monitoring company; and
Slide 21: Board of Directors
Board of Directors Mr. Danzig most recently served as Vice President, Assistant General Counsel and Assistant Secretary of L3Harris Technologies, Inc., a global aerospace and defense Allen Danzig technology contractor, with $17 billion in annual revenue. Prior to its merger with Harris Corporation i
Slide 22: Investment Highlights
Investment Highlights Highlight Features Large Addressable • $800B+ global addressable market over the next 10 years through multi channel growth in diabetes Market • $7.5B global market for CGM in 2022, with strong growth in revenue and userbase • Integration with insulin delivery devices for close
Slide 23: Facts and Cap Table
Facts and Cap Table Exchange: Ticker NASDAQ: GCTK Shares Market Cap Headquarters Total Shares Issued & Outstanding 22,868,663* Rutherford, NJ Invested to date Options and Warrants 8,786,578 (exercise prices $1.36-$100.75) ~ $75,000,000 Stock Price Fully Diluted 31,655,241 $0.22 52 Week Range Market
Slide 24: Thank you!
Thank you! NASDAQ: GCTK 301 17N, Suite 800 Rutherford, NJ 07070 info@glucotrack.com www.glucotrack.com